Fresenius Medical Care (FMS) reported Q2 adjusted earnings Tuesday of 0.91 euro ($1.05) per share, up from 0.72 euro a year earlier.

Revenue for the quarter ended June 30 was 4.79 billion euros, compared with 4.77 billion euros a year earlier.

Analysts polled by FactSet expected 4.93 billion euros.

For fiscal 2025, the company reaffirmed its guidance for positive to low single-digit percent revenue growth year over year. Analysts surveyed by FactSet expect revenue of 19.55 billion euros.

Shares of the company were down more than 1% in recent Tuesday premarket activity.